PP
RGLS

Paloma Partners’s Regulus Therapeutics RGLS Stock Holding History

Paloma Partners’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,217
Closed -$144K – 2373
2017
Q2 		$144K Buy
+1,217
New +$203K ﹤0.01% 2045
2017
Q1 		– Sell
-204
Closed -$55K – 2196
2016
Q4 		$55K Buy
+204
New +$66.3K ﹤0.01% 1925

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Paloma Partners's RGLS Position: Q3 2017 in Review

Paloma Partners sold out of Regulus Therapeutics (RGLS) in Q3 2017, closing a stake of 1,217 shares — an estimated $144K sold.

Paloma Partners first reported a position in RGLS in Q4 2016 and held it in 2 quarters. The position peaked at $144K in Q2 2017. 48 funds tracked by Wall St. Rank hold RGLS as of Q3 2017.

  • Paloma Partners reported no remaining Regulus Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 1,217 Regulus Therapeutics shares in Q3 2017, an estimated $144K.
  • Paloma Partners first reported a position in Regulus Therapeutics in Q4 2016 and held it in 2 quarters.
  • Paloma Partners's Regulus Therapeutics position peaked at $144K in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.